hemophilia
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
First In Vivo Human Genome Editing to Be Tested in New Clinical Trial
First In Vivo Human Genome Editing to Be Tested in New Clinical Trial
Abby Olena | May 18, 2017
Sangamo Therapeutics will use zinc finger nucleases to introduce the gene for a missing clotting factor into the livers of men with hemophilia B.
Targeting DNA
Targeting DNA
Jef Akst | Jun 1, 2012
After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.
Gene Editing Treats Blood Disease
Annie Gottlieb | Jun 27, 2011
Revising a dysfunctional gene in vivo for the first time, researchers successfully restore blood clotting in hemophiliac mice.